Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in... PharmacoEconomics Open (2018) 2:153–163 https://doi.org/10.1007/s41669-017-0048-x OR IGINAL RESEARCH ARTIC L E Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) 1 1 1 2 • • • • Martina Garau Grace Hampson Nancy Devlin Nicola Amedeo Mazzanti Antonio Profico Published online: 22 August 2017 The Author(s) 2017. This article is an open access publication Abstract Conclusions MCDA can be used to elicit the views of Background Healthcare decision makers need to make different stakeholder groups and has the potential to trade-offs between different elements of value of new structure and inform reimbursement decisions. treatments. Multicriteria decision analysis (MCDA) pro- vides a framework that can help decision makers to understand stakeholders’ preferences and be explicit about Key Points for Decision Makers the trade-offs that are being made. Objective The objective of this study was to use MCDA to Multicriteria decision analysis (MCDA) provides a obtain preferences and views on decision criteria across framework that can help decision makers to three stakeholder groups (patients, clinicians and payers) in understand stakeholders’ preferences and be explicit Italy and to use these to assess the performance of obinu- about the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics - Open Springer Journals

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Download PDF
11 pages

Loading next page...
 
/lp/springer_journal/applying-a-multicriteria-decision-analysis-mcda-approach-to-elicit-IhVgQWsPzq
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes
ISSN
2509-4262
eISSN
2509-4254
DOI
10.1007/s41669-017-0048-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics Open (2018) 2:153–163 https://doi.org/10.1007/s41669-017-0048-x OR IGINAL RESEARCH ARTIC L E Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) 1 1 1 2 • • • • Martina Garau Grace Hampson Nancy Devlin Nicola Amedeo Mazzanti Antonio Profico Published online: 22 August 2017 The Author(s) 2017. This article is an open access publication Abstract Conclusions MCDA can be used to elicit the views of Background Healthcare decision makers need to make different stakeholder groups and has the potential to trade-offs between different elements of value of new structure and inform reimbursement decisions. treatments. Multicriteria decision analysis (MCDA) pro- vides a framework that can help decision makers to understand stakeholders’ preferences and be explicit about Key Points for Decision Makers the trade-offs that are being made. Objective The objective of this study was to use MCDA to Multicriteria decision analysis (MCDA) provides a obtain preferences and views on decision criteria across framework that can help decision makers to three stakeholder groups (patients, clinicians and payers) in understand stakeholders’ preferences and be explicit Italy and to use these to assess the performance of obinu- about the

Journal

PharmacoEconomics - Open – Springer Journals

Published: Aug 22, 2017

References

  • A review of health technology appraisals: case studies in oncology
    Shah, KK; Mestre-Ferrandiz, J; Towse, A; Smyth, EN
  • Incorporating multiple criteria in HTA: methods and processes. OHE Monograph
    Devlin, N; Sussex, J
  • Integrating patients’ views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences
    Danner, M; Hummel, JM; Volz, F; Manen, JG; Wiegard, B; Dintsios, CM
  • Multiple criteria decision analysis for health care decision making-an introduction: report 1 of the ISPOR MCDA emerging good practices task force
    Thokala, P; Devlin, N; Marsh, K; Baltussen, R; Boysen, M; Kalo, Z
  • Implementation of EUnetHTA core Model(R) in Lombardia: the VTS framework
    Radaelli, G; Lettieri, E; Masella, C; Merlino, L; Strada, A; Tringali, M
  • Multi-criteria decision analysis to support healthcare decisions
    Castro, H; Tringali, M; Cleemput, I; Devriese, S; Leoni, O; Lettieri, E
  • Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study
    Wahlster, P; Goetghebeur, M; Schaller, S; Kriza, C; Kolominsky-Rabas, P
  • Validity and reliability of value assessment frameworks for new cancer drugs
    Bentley, TG; Cohen, JT; Elkin, EB; Huynh, J; Mukherjea, A; Neville, TH
  • Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation
    Wagner, M; Khoury, H; Willet, J; Rindress, D; Goetghebeur, M
  • Accountability for reasonableness: an update
    Daniels, N; Sabin, JE
  • Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada
    Tony, M; Wagner, M; Khoury, H; Rindress, D; Papastavros, T; Oh, P
  • Does technique matter: a pilot study exploring weighting techniques for a multi-criteria decision support framework
    Til, J; Groothuis-Oudshoorn, C; Lieferink, M; Dolan, J; Goetghebeur, M
  • Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
    Sehn, LH; Chua, N; Mayer, J; Dueck, G; Trneny, M; Bouabdallah, K
  • Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin’s lymphoma: correlation of complete response, time-to-event and overall survival end points
    Lee, L; Wang, L; Crump, M
  • A framework for group decision using a MCDA model: sharing, aggregating or comparing individual information?
    Belton, V; Pictet, J
  • Three questions to ask when examining MCDA
    Claxton, K
  • Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force
    Marsh, K; IJmerzan, M; Thokala, P; Baltussen, R; Boysen, M; Kalo, Z
  • Multi-criteria decision analysis to support healthcare decisions
    Garau, M; Devlin, NJ
  • Which health technologies should be funded? A prioritization framework based explicitly on value for money
    Golan, O; Hansen, P
  • Operationalizing value-based pricing of medicines: a taxonomy of approaches
    Sussex, J; Towse, A; Devlin, N
  • Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence
    Culyer, A; McCabe, C; Briggs, A; Claxton, K; Buxton, M; Akehurst, R
  • Local health care expenditure plans and their opportunity costs
    Karlsberg Schaffer, S; Sussex, J; Devlin, N; Walker, A
  • Searching for cost effectiveness thresholds in the NHS
    Appleby, J; Devlin, N; Parkin, D; Buxton, M; Chalkidou, K
  • Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
    Claxton, K; Martin, S; Soares, M; Rice, N; Spackman, E; Hinde, S
  • Amplifying each patient’s voice: a systematic review of multi-criteria decision analyses involving patients
    Marsh, K; Caro, JJ; Hamed, A; Zaiser, E
  • Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA
    Mühlbacher, AC; Kaczynski, A
  • Multi-criteria decision analysis to support healthcare decisions
    Phillips, LD
  • Health technology prioritization: which criteria for prioritizing new technologies and what are their relative weights?
    Golan, O; Hansen, P; Kaplan, G; Tal, O